Designing a Library of TCR T Cell Therapy Products that Precisely Target Mutant KRAS

  • Selecting and validating high value KRAS targets systemized cell biology assays
  • Defining potent and selective TCR assets that form the foundation of differentiated TCR T therapy products
  • Scaling manufacturing and clinical trial design to enable meet the needs of highly personalized cell therapies